中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 5
May  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(5): 1217-1222

Epidemiological features of chronic liver disease with different etiologies comorbid with type 2 diabetes mellitus

DOI: 10.12449/JCH260532

  • Division of Liver Disease Center，Public Health Clinical Center Affiliated to Shandong University，Jinan 250101，China

Research funding:

Key R&D Plan of Shandong Province (2021SFGC0504)

More Information
  • Corresponding author: LI Qiang， doctorliqiang@aliyun.com （ORCID： 0000-0002-8667-4676）
  • Received Date: 2025-05-02
  • Accepted Date: 2025-11-26
  • Published Date: 2026-05-25
    Abstract
  • Both chronic liver disease （CLD） and type 2 diabetes mellitus （T2DM） are major public health issues worldwide， and there is a significant difference in the prevalence rate of T2DM across patients with CLD of different etiologies. Chronic hepatitis C virus infection， dysregulation of fat metabolism， and excessive drinking not only lead to CLD， but also increase the prevalence rate of T2DM. It remains unclear whether chronic hepatitis B virus infection can cause an increase in the risk of T2DM， although the prevalence rate of T2DM significantly increases with disease progression in patients with chronic hepatitis B， and there is still a lack of large-sample evidence for the association between autoimmune liver disease and T2DM. In addition， T2DM may increase the risk of end-stage liver diseases such as cirrhosis and hepatocellular carcinoma. Therefore， early diagnosis and individualized management of T2DM are of great importance for improving the prognosis of patients with CLD.

     

    • FullText(HTML)
  • loading
    • References(44)
  • [1]
    DEVARBHAVI H, ASRANI SK, ARAB JP, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79( 2): 516- 537. DOI: 10.1016/j.jhep.2023.03.017.
    [2]
    HICKMAN IJ, MACDONALD GA. Impact of diabetes on the severity of liver disease[J]. Am J Med, 2007, 120( 10): 829- 834. DOI: 10.1016/j.amjmed.2007.03.025.
    [3]
    YU YF, TONG KK, HU G, et al. Love-hate relationship between hepatitis B virus and type 2 diabetes: A Mendelian randomization study[J]. Front Microbiol, 2024, 15: 1378311. DOI: 10.3389/fmicb.2024.1378311.
    [4]
    LIU DF, ZHOU LY, ZHANG XY, et al. Significantly decreased islet β cell function is closely associated with hyperglycemia in chronic hepatitis B patients[J]. Int J Endocrinol, 2021, 2021: 1264707. DOI: 10.1155/2021/1264707.
    [5]
    SHIN HJ, PARK YH, KIM SU, et al. Hepatitis B virus X protein regulates hepatic glucose homeostasis via activation of inducible nitric oxide synthase[J]. J Biol Chem, 2011, 286( 34): 29872- 29881. DOI: 10.1074/jbc.M111.259978.
    [6]
    JIANG C, ZHANG ZH, LI JX. Current status of drug therapy for chronic hepatitis B[J]. World J Gastroenterol, 2025, 31( 2): 99443. DOI: 10.3748/wjg.v31.i2.99443.
    [7]
    LEI SY, CHEN SH, ZHAO XY, et al. Hepatitis B virus infection and diabetes mellitus: The Kailuan prospective cohort study in China[J]. Hepatol Int, 2020, 14( 5): 743- 753. DOI: 10.1007/s12072-020-10086-2.
    [8]
    BAKER F ABU, ZEINA AR, NATOUR RT, et al. Prevalence and risk factors of type 2 diabetes mellitus among hepatitis B virus patients: A large retrospective cohort study[J]. Int J Med Sci, 2025, 22( 3): 716- 722. DOI: 10.7150/ijms.104839.
    [9]
    SPRADLING PR, SIMONS B, NARAYANAN M, et al. Incidence of diabetes mellitus in a population-based cohort of persons with chronic hepatitis B virus infection[J]. J Viral Hepat, 2013, 20( 7): 510- 513. DOI: 10.1111/jvh.12071.
    [10]
    WANG YY, LIN SY, SHEU WH, et al. Obesity and diabetic hyperglycemia were associated with serum alanine aminotransferase activity in patients with hepatitis B infection[J]. Metabolism, 2010, 59( 4): 486- 491. DOI: 10.1016/j.metabol.2009.07.038.
    [11]
    XIE JZ, WANG X, WANG XR, et al. Assessing the impact of comorbid type 2 diabetes mellitus on the disease burden of chronic hepatitis B virus infection and its complications in China from 2006 to 2030: A modeling study[J]. Glob Health Res Policy, 2024, 9( 1): 5. DOI: 10.1186/s41256-024-00345-2.
    [12]
    AYTUG S, REICH D, SAPIRO LE, et al. Impaired IRS-1/PI3 -kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes[J]. Hepatology, 2003, 38( 6): 1384- 1392. DOI: 10.1016/j.hep.2003.09.012.
    [13]
    CUA IHY, HUI JM, BANDARA P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines[J]. Hepatology, 2007, 46( 1): 66- 73. DOI: 10.1002/hep.21703.
    [14]
    WHO. Hepatitis C[EB/OL].( 2024-04-09)[ 2025-03-12]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
    [15]
    HUANG JF, DAI CY, HWANG SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: An epidemiological link with virological implication[J]. Am J Gastroenterol, 2007, 102( 6): 1237- 1243. DOI: 10.1111/j.1572-0241.2007.01181.x.
    [16]
    JEONG D, KARIM ME, WONG S, et al. Impact of HCV infection and ethnicity on incident type 2 diabetes: Findings from a large population-based cohort in British Columbia[J]. BMJ Open Diabetes Res Care, 2021, 9( 1): e002145. DOI: 10.1136/bmjdrc-2021-002145.
    [17]
    IMAZEKI F, YOKOSUKA O, FUKAI K, et al. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: Comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients[J]. Liver Int, 2008, 28( 3): 355- 362. DOI: 10.1111/j.1478-3231.2007.01630.x.
    [18]
    WHITE DL, RATZIU V, EL-SERAG HB. Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis[J]. J Hepatol, 2008, 49( 5): 831- 844. DOI: 10.1016/j.jhep.2008.08.006.
    [19]
    LI X, XU HQ, GAO Y, et al. Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China[J]. Medicine, 2017, 96( 13): e6508. DOI: 10.1097/MD.0000000000006508.
    [20]
    JANUARIO E, BARAKAT A, RAJSUNDAR A, et al. A comprehensive review of pathophysiological link between non-alcoholic fatty liver disease, insulin resistance, and metabolic syndrome[J]. Cureus, 2024, 16( 12): e75677. DOI: 10.7759/cureus.75677.
    [21]
    KOZLITINA J, SOOKOIAN S. Global epidemiological impact of PNPLA3 I148M on liver disease[J]. Liver Int, 2025, 45( 3): e16123. DOI: 10.1111/liv.16123.
    [22]
    CAO LM, AN Y, LIU HY, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: A systematic review and meta-analysis[J]. BMC Med, 2024, 22( 1): 101. DOI: 10.1186/s12916-024-03315-0.
    [23]
    AMPUERO J, ALLER R, GALLEGO-DURÁN R, et al. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH[J]. J Hepatol, 2020, 73( 1): 17- 25. DOI: 10.1016/j.jhep.2020.02.028.
    [24]
    FUKUDA T, HAMAGUCHI M, KOJIMA T, et al. Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men[J]. Eur J Gastroenterol Hepatol, 2016, 28( 12): 1443- 1449. DOI: 10.1097/MEG.0000000000000736.
    [25]
    ZHOU M, BO T, FAN XD, et al. Metabolic dysfunction-associated fatty liver disease: A central hub in systemic metabolic dysregulation[J]. J Clin Hepatol, 2025, 41( 9): 1725- 1728. DOI: 10.12449/JCH250902.

    周蒙, 薄涛, 范修德, 等. 代谢相关脂肪性肝病: 全身代谢性紊乱的核心枢纽之一[J]. 临床肝胆病杂志, 2025, 41( 9): 1725- 1728. DOI: 10.12449/JCH250902.
    [26]
    DUAN HX, JIANG YY, WU TY, et al. The genetic association between nonalcoholic fatty liver disease and type 2 diabetes mellitus in different body mass index categories: A bidirectional Mendelian randomization study[J]. J Clin Hepatol, 2024, 40( 10): 1992- 1999. DOI: 10.12449/JCH241011.

    段浩鑫, 江宇泳, 吴亭彧, 等. 基于双向孟德尔随机化的不同BMI分型非酒精性脂肪性肝病与2型糖尿病的遗传关联分析[J]. 临床肝胆病杂志, 2024, 40( 10): 1992- 1999. DOI: 10.12449/JCH241011.
    [27]
    HAN XY, ZHANG X, LIU ZQ, et al. Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus[J]. J Diabetes, 2024, 16( 5): e13564. DOI: 10.1111/1753-0407.13564.
    [28]
    EGUCHI Y, HYOGO H, ONO M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: A multicenter large retrospective study[J]. J Gastroenterol, 2012, 47( 5): 586- 595. DOI: 10.1007/s00535-012-0533-z.
    [29]
    YABE D, SEINO Y, FUKUSHIMA M, et al. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians[J]. Curr Diab Rep, 2015, 15( 6): 36. DOI: 10.1007/s11892-015-0602-9.
    [30]
    LI YM, FAN JG. Guidelines of prevention and treatment for alcoholic liver disease(2018, China)[J]. J Dig Dis, 2019, 20( 4): 174- 180. DOI: 10.1111/1751-2980.12687.
    [31]
    JENSEN AH, WINTHER-SØRENSEN M, BURISCH J, et al. Autoimmune liver diseases and diabetes: A propensity score matched analysis and a proportional meta-analysis[J]. Liver Int, 2023, 43( 11): 2479- 2491. DOI: 10.1111/liv.15720.
    [32]
    N’KONTCHOU G, PARIES J, HTAR MTT, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis[J]. Clin Gastroenterol Hepatol, 2006, 4( 8): 1062- 1068. DOI: 10.1016/j.cgh.2006.05.013.
    [33]
    RAYNARD B, BALIAN A, FALLIK D, et al. Risk factors of fibrosis in alcohol-induced liver disease[J]. Hepatology, 2002, 35( 3): 635- 638. DOI: 10.1053/jhep.2002.31782.
    [34]
    BALBI M, DONADON V, GHERSETTI M, et al. Alcohol and HCV chronic infection are risk cofactors of type 2 diabetes mellitus for hepatocellular carcinoma in Italy[J]. Int J Environ Res Public Health, 2010, 7( 4): 1366- 1378. DOI: 10.3390/ijerph7041366.
    [35]
    HAMEED I, MASOODI SR, MIR SA, et al. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition[J]. World J Diabetes, 2015, 6( 4): 598- 612. DOI: 10.4239/wjd.v6.i4.598.
    [36]
    LV D, WANG H, LENG Y, et al. Association between diabetes mellitus and primary biliary cholangitis: A two-sample Mendelian randomization study[J]. Front Endocrinol, 2024, 15: 1362584. DOI: 10.3389/fendo.2024.1362584.
    [37]
    MATSUMOTO N, OGAWA M, MATSUOKA S, et al. Prevalence and risk factors of diabetes mellitus in patients with autoimmune hepatitis[J]. Intern Med, 2016, 55( 8): 879- 885. DOI: 10.2169/internalmedicine.55.4957.
    [38]
    WANG Q, ZHANG CR, TANG YM. Research advances in glucose and lipid metabolism disorders in different types of chronic liver diseases[J]. J Clin Hepatol, 2022, 38( 8): 1937- 1940. DOI: 10.3969/j.issn.1001-5256.2022.08.043.

    王倩, 张宸瑞, 唐映梅. 不同类型慢性肝病糖脂代谢紊乱研究进展[J]. 临床肝胆病杂志, 2022, 38( 8): 1937- 1940. DOI: 10.3969/j.issn.1001-5256.2022.08.043.
    [39]
    BOSCH DE, ZEN Y, BOUKHAR SA, et al. Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: A clinical and pathological study in an uncommon but emerging setting[J]. Virchows Arch, 2021, 479( 6): 1131- 1143. DOI: 10.1007/s00428-021-03183-6.
    [40]
    SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013[J]. Lancet, 2015, 386( 10003): 1546- 1555. DOI: 10.1016/S0140-6736(15)61412-X.
    [41]
    GUNTIPALLI P, PAKALA R, KUMARI GARA S, et al. Worldwide prevalence, genotype distribution and management of hepatitis C[J]. Acta Gastroenterol Belg, 2021, 84( 4): 637- 656. DOI: 10.51821/84.4.015.
    [42]
    TENG ML, NG CH, HUANG DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2023, 29( Suppl): S32- S42. DOI: 10.3350/cmh.2022.0365.
    [43]
    AMONKER S, HOUSHMAND A, HINKSON A, et al. Prevalence of alcohol-associated liver disease: A systematic review and meta-analysis[J]. Hepatol Commun, 2023, 7( 5): e0133. DOI: 10.1097/HC9.0000000000000133.
    [44]
    SEBODE M, KLOPPENBURG A, AIGNER A, et al. Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: Rising prevalences based on ICD codes, yet deficits in medical treatment[J]. Z Gastroenterol, 2020, 58( 5): 431- 438. DOI: 10.1055/a-1135-9306.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (26) PDF downloads(9) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return